ReviewFrontiers in cardiovascular medicine2020
Antibodies and Immunity During Kawasaki Disease.
Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Kawasaki Disease from a Single-Referral Center in Morocco with Emphasis on Diagnosis Delay and Treatment Onset.Turkish archives of pediatrics · 2025Article
- Serology supportive of recent coxsackievirus B infection is correlated with multisystem inflammatory syndrome in children (MIS-C).Microbiology spectrum · 2025Article
- MFG-E8 in Kawasaki Disease: Role in Endothelial Injury and Diagnostic Potential.Journal of inflammation research · 2025Article
- The Future of Kawasaki Disease Diagnosis: Liquid Biopsy May Hold the Key.International journal of molecular sciences · 2024Review
- Transcriptome meta-analysis of Kawasaki disease in humans and mice.Frontiers in pediatrics · 2024Article
- Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: Common Inflammatory Pathways of Two Distinct Diseases.Rheumatic diseases clinics of North America · 2023Review
- Intravenous Immunoglobulin in Kawasaki Disease-Evolution and Pathogenic Mechanisms.Diagnostics (Basel, Switzerland) · 2023Review
- Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.Inflammation · 2023Article
- Identification of Hub Biomarkers and Immune and Inflammation Pathways Contributing to Kawasaki Disease Progression with RT-qPCR Verification.Journal of immunology research · 2023Article
- Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Clonal expansion and markers of directed mutation of IGHV4-34 B cells in plasmablasts during Kawasaki disease.Molecular immunology · 2022Article
- Adaptive Immunity and the Risk of Autoreactivity in COVID-19.International journal of molecular sciences · 2021Review
- Why are we vaccinating children against COVID-19?Toxicology reports · 2021Article
- A Diagnostic Model for Kawasaki Disease Based on Immune Cell Characterization From Blood Samples.Frontiers in pediatrics · 2021Article
- The up-to-date pathophysiology of Kawasaki disease.Clinical & translational immunology · 2021Review
- Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment.Frontiers in pediatrics · 2020Review
- COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cause of Kawasaki disease (KD), the leading cause of acquired heart disease in children, is currently unknown. Epidemiology studies support that an infectious disease is involved in at least starting the inflammatory cascade set off during KD. Clues from epidemiology support that humoral immunity can have a protective effect. However, the role of the immune system, particularly of B cells and antibodies, in pathogenesis of KD is still unclear. Intravenous immunoglobulin (IVIG) and other therapies targeted at modulating inflammation can prevent development of coronary aneurysms. A number of autoantibody responses have been reported in children with KD and antibodies have been generated from aneurysmal plasma cell infiltrates. Recent reports show that children with KD have similar plasmablast responses as other children with infectious diseases, further supporting an infectious starting point. As ongoing studies are attempting to identify the etiology of KD through study of antibody responses, we sought to review the role of humoral immunity in KD pathogenesis, treatment, and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.